PAREXEL Experts to Participate in 42nd Annual Drug Information
Association Meeting
Wednesday June 14, 10:32 am ET
BOSTON, June 14 /PRNewswire-FirstCall/ -- Several experts from
PAREXEL International Corporation (Nasdaq: PRXL - News), a leading
global bio/pharmaceutical services organization, will chair sessions
and give presentations during the 42nd Annual Drug Information
Association (DIA) Meeting, to be held June 18 - 22, 2006 at the
Pennsylvania Convention Center in Philadelphia. Significant industry
issues will be addressed, including the changing paradigm of
clinical development programs, biosimilars, biomarkers in drug
development, and success factors for global applications of
biotechnology-derived products.
PAREXEL will also have a major presence in the exhibit hall at
booths 925 - 1024 to showcase services from its business units:
PAREXEL Consulting, PAREXEL Clinical Research, PAREXEL Medical
Communications and its technology subsidiary Perceptive Informatics,
Inc.
PAREXEL Presentations
Monday, June 19
Chair: Alberto Grignolo, Corporate Vice President and
General
Manager, PAREXEL Consulting
Session: "Changing the Paradigm: Innovation Oncology Drug
Clinical
Development Programs in the Age of Critical Path and
Personalized Medicine"
Time: 10:30 a.m. - 12:00 p.m.
Tuesday, June 20
Chair: Cecil Nick, Director, PAREXEL Consulting, UK
Session: "Biosimilars in Europe: A Dawning Reality"
Time: 10:30 a.m. - 12:00 p.m.
Chair: Alberto Grignolo, Corporate Vice President and
General
Manager, PAREXEL Consulting
Session: "Biomarkers in Drug Development: A Blessing or a
Curse?"
Time: 1:30 p.m. - 3:00 p.m.
Wednesday, June 21
Presenter: David Davenport, Senior Director, Business
Development,
Perceptive Informatics
Session: "Tracking Patient Enrollment from Inquiry to
Randomization and
Beyond"
Time: 3:30 p.m. - 5:00 p.m.
Chair: Gabriele Schaeffner, Principal Consultant, PAREXEL
Consulting
Session: "An Analysis of the Success Factors of Global
Applications of
Biotechnology-derived Products"
Time: 3:30 p.m. - 5:00 p.m.
Thursday, June 22
Chair: David Skarinsky, Principal Consultant, PAREXEL
Consulting
Session: "Microdosing Studies: State of Technology and US
Regulatory
Requirements"
Time: 8:30 a.m. - 10:00 a.m.
Chair: Nicola Burke, Manager, PAREXEL Consulting
Session: "Planning and Conducting Successful Investigators'
Meetings"
Time: 10:30 a.m. - 12:00 p.m.
Chair: Diego Glancszpigel, Director, PAREXEL International,
Latin
America
Session: "How to Assure Quality When Clinical Trials Are
Conducted in
Developing Countries"
Time: 10:30 a.m. - 12:00 p.m.
About the Conference
The Annual DIA Meeting is attended by pharmaceutical, biotechnology
and regulatory professionals from around the world. This year's
meeting will have over 350 sessions and more than 1,000 speakers.
Professionals who bring new medicines and vaccines to populations
around the world gather at the DIA meeting to learn about best
practices. For more information visit the DIA website at
http://www.diahome.org.
About PAREXEL
PAREXEL International Corporation is a leading global
bio/pharmaceutical services organization, providing a broad range of
knowledge-based contract research, medical marketing and consulting
services to the worldwide pharmaceutical, biotechnology and medical
device industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical education
and reimbursement. Perceptive Informatics, Inc., a subsidiary of
PAREXEL, provides advanced technology solutions, including medical
imaging, Clinical Trial Management Systems (CTMS), Interactive Voice
Response Systems (IVRS) and integration services. Headquartered near
Boston, Massachusetts, PAREXEL operates in 52 locations throughout
39 countries around the world, and has approximately 5,445
employees. For more information about PAREXEL International visit
http://www.PAREXEL.com.
This release contains "forward-looking" statements regarding future
results and events. For this purpose, any statements contained
herein that are not statements of historical fact may be deemed
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "intends," "appe
ars," "estimates," "projects," "targets" and similar expressions are
also intended to identify forward-looking statements. The forward-
looking statements in this release involve a number of risks and
uncertainties. The Company's actual future results may differ
significantly from the results discussed in the forward- looking
statements contained in this release. Important factors that might
cause such a difference include, but are not limited to, risks
associated with: actual operating performance; actual expense
savings and other operating improvements resulting from recent
restructurings; the loss, modification, or delay of contracts which
would, among other things, adversely impact the Company's
recognition of revenue included in backlog; the amendment or
interpretation of Financial Accounting Standards Board Statement No.
123 (revised 2004), Share-Based Payment ("Statement 123R"), which
could change the Company's current assessment of the effects of the
adoption of Statement 123R on the acceleration of equity grants, the
assumptions inherent in equity pricing models under Statement 123R
and the final results of the closing of the Company's books for
future financial periods; the Company's dependence on certain
industries and clients; the Company's ability to win new business,
manage growth and costs, and attract and retain employees; the
Company's ability to complete additional acquisitions and to
integrate newly acquired businesses or enter into new lines of
business; the impact on the Company's business of government
regulation of the drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and
other risks. Such factors and others are discussed more fully in the
section entitled "Risk Factors" of the Company's Quarterly Report on
Form 10-Q for the period ended March 31, 2006 as filed with the SEC
on May 9, 2006, which "Risk Factors" discussion is incorporated by
reference in this press release. The forward-looking statements
included in this press release represent the Company's estimates as
of the date of this release. The Company specifically disclaims any
obligation to update these forward-looking statements in the future.
These forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International
Corporation, and Perceptive Informatics is a trademark of Perceptive
Informatics, Inc. All other names or marks may be registered
trademarks or trademarks of their respective business and are hereby
acknowledged.
Media Contact:
Jennifer Baird, Director of Public Relations
PAREXEL International
Tel: +1.781.434.4409
Email: [EMAIL PROTECTED]
---------------------------------------------------------------------
-----------
Source: PAREXEL International Corporation
------------------------ Yahoo! Groups Sponsor --------------------~-->
Something is new at Yahoo! Groups. Check out the enhanced email design.
http://us.click.yahoo.com/SISQkA/gOaOAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->
http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/
<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
